

Contents

List of Contributors XI

Preface XV

A Personal Foreword XVII

1	Introduction	1
	<i>Andrew S. Bell and Spiros Liras</i>	
2	Toward a New Generation of PDE5 Inhibitors through Advances in Medicinal Chemistry	9
	<i>Dafydd R. Owen</i>	
2.1	Introduction	9
2.2	The First-Generation Agents	10
2.3	PDE5 as a Mechanism and Alternative Indications Beyond MED	11
2.4	A Summary of PDE5 Chemotypes Reported Post-2010	11
2.5	Second-Generation PDE5 Inhibitors from Pfizer: Pyrazolopyrimidines	12
2.6	Second-Generation PDE5 Inhibitors from Pfizer: Pyridopyrazinones	18
2.7	Conclusions	25
	References	25
3	PDE4: New Structural Insights into the Regulatory Mechanism and Implications for the Design of Selective Inhibitors	29
	<i>Jayvardhan Pandit</i>	
3.1	Introduction	29
3.2	Isoforms, Domain Organization, and Splice Variants	30
3.3	Structural Features of the Catalytic Site	31
3.4	Regulation of PDE4 Activity	32
3.5	Crystal Structure of Regulatory Domains of PDE4	33
3.6	UCR2 Interaction and Selectivity	38
3.7	Conclusions	39
	References	40

4	PDE4: Recent Medicinal Chemistry Strategies to Mitigate Adverse Effects	45
	<i>Etzer Darout, Elnaz Menhaji-Klotz, and Thomas A. Chappie</i>	
4.1	Introduction	45
4.2	Brief Summary of pan-PDE4 Inhibitors	46
4.2.1	Rolipram	47
4.2.2	Roflumilast	48
4.2.3	Cilomilast	48
4.2.4	Apremilast	49
4.3	PDE4 Strategies to Avoid Gastrointestinal Events	49
4.3.1	Allosteric Modulation	49
4.3.2	PDE4D Selectivity	53
4.3.3	Pfizer	53
4.3.4	Novartis	54
4.3.5	Merck-Frosst	54
4.3.6	GEBR-7b	55
4.3.7	PDE4B Selectivity	55
4.3.8	Asahi Kasei	56
4.3.9	GlaxoSmithKline	56
4.3.10	Pfizer	57
4.3.11	Tissue Targeting	57
4.3.12	Polypharmacology	58
4.3.13	Olanzapine Derivatives	58
4.4	Conclusions	59
	References	60
5	The Function, Enzyme Kinetics, Structural Biology, and Medicinal Chemistry of PDE10A	65
	<i>Thomas A. Chappie and Patrick Verhoest</i>	
5.1	Enzymology and Protein Structure	66
5.2	Papaverine-Related PDE10A Inhibitors	69
5.3	MP-10/PF-2545920 Class of Inhibitors	72
5.4	PF-2545920/MP-Inspired Inhibitors	74
5.5	PF-2545920/Papaverine/Quinazoline Hybrid Series of Inhibitors	75
5.6	PET Ligand Development	77
5.7	Summary and Future	79
	References	79
6	The State of the Art in Selective PDE2A Inhibitor Design	83
	<i>Christopher W. am Ende, Bethany L. Kormos, and John M. Humphrey</i>	
6.1	Introduction	83
6.2	Selective PDE2A Inhibitors	84
6.2.1	Bayer	84
6.2.2	Altana AG	85
6.2.3	Biotie Therapies	87

6.2.4	Boehringer Ingelheim	88
6.2.5	Janssen	89
6.2.6	Lundbeck	92
6.2.7	Merck	93
6.2.8	Neuro3d	95
6.2.9	Pfizer	95
6.3	Methods	100
6.4	Conclusions	100
	References	101
7	Crystal Structures of Phosphodiesterase 9A and Insight into Inhibitor Discovery	105
	<i>Hengming Ke, Yousheng Wang, Yiqian Wan, and Hai-Bin Luo</i>	
7.1	Introduction	105
7.2	Subtle Asymmetry of the PDE9 Dimer in the Crystals	105
7.3	The Structure of the PDE9 Catalytic Domain	107
7.4	Interaction of Inhibitors with PDE9	108
7.5	Implication on Inhibitor Selectivity	110
	References	114
8	PDEs as CNS Targets: PDE9 Inhibitors for Cognitive Deficit Diseases	117
	<i>Michelle M. Claffey, Christopher J. Helal, and Xinjun Hou</i>	
8.1	PDE9A Enzymology and Pharmacology	117
8.2	Crystal Structures of PDE9A Inhibitors	119
8.3	Medicinal Chemistry Efforts toward Identifying PDE9A Inhibitors for Treating Cognitive Disorders	120
8.3.1	Bayer	120
8.3.2	Pfizer	125
8.3.3	Boehringer Ingelheim	129
8.3.4	Sun Yat-Sen University, China	132
8.3.5	Envivo Pharmaceuticals	133
8.4	Analysis of CNS Desirability of PDE9A Inhibitors	135
8.5	Conclusions	135
	References	137
9	Phosphodiesterase 8B	141
	<i>Stephen W. Wright</i>	
9.1	Introduction	141
9.2	Identification	141
9.3	Properties	142
9.4	Expression and Tissue Distribution	143
9.5	Functions of PDE8B	143
9.5.1	Thyroid	144
9.5.2	Adrenal Gland	144

9.5.3	Pancreatic Islets	144
9.6	Inhibitors and Potential Therapeutic Uses	145
	References	150
10	Selective New Small-Molecule Inhibitors of Phosphodiesterase 1	155
	<i>John M. Humphrey</i>	
10.1	Introduction	155
10.2	PDE1 Enzymology	155
10.3	PDE1 Inhibitors	156
10.3.1	Non-Selective PDE1 Inhibitors	156
10.3.2	Selective PDE1 inhibitors	158
10.4	Conclusion	161
	References	163
11	Recent Advances in the Development of PDE7 Inhibitors	165
	<i>Nigel A. Swain and Rainer Gewalt</i>	
11.1	Introduction	165
11.1.1	PDE7: Subtypes and Distribution	165
11.1.2	Rationale for PDE7 as a Therapeutic Target	166
11.2	Historical Development of PDE7 Inhibitors	166
11.2.1	Early Examples of Nonselective and Selective Lead Matter	166
11.2.2	Developing Selective Lead Matter from Nonselective Hits	167
11.2.3	Targeting PDE4/7 Dual Inhibitors	168
11.3	Recent Advances in the Discovery of PDE7 Inhibitors for Peripheral Therapeutic Benefit	169
11.3.1	PDE7 Inhibitors for the Treatment of T Cell-Related Disorders	169
11.3.1.1	Developments in PDE7 Inhibitors for the Treatment of Airway-Related Disorders	170
11.3.1.2	Developments in PDE7 Inhibitors for the Treatment of Nonairway-Related Disorders	171
11.3.1.3	Summary of T-Cell-Related Research	171
11.3.2	PDE7 Inhibitors for the Treatment of Neuropathic Pain	172
11.4	Recent Advances in the Discovery of PDE7 Inhibitors for CNS-Related Disorders	173
11.4.1	Creating PDE7 Inhibitors by Ligand-Based Virtual Screening Methods	173
11.4.2	Repositioning PDE7 Inhibitors Designed for the Treatment of Peripheral Diseases	176
11.5	Recent Advances in the Discovery of Dual PDE7 Inhibitors	178
11.5.1	Dual PDE4/7 Inhibitors	178
11.5.2	Dual PDE7/8 Inhibitors	180
11.6	Identifying Next-Generation PDE7 Inhibitors	181
11.6.1	Emerging Chemotypes as Novel PDE7 Inhibitors	181
11.6.2	Novel Methods to Identify PDE7 Inhibitors	182
11.6.2.1	Computational Methods to Identify New PDE7 Inhibitors	182

11.6.2.2	Fission Yeast-Based HTS to Identify New PDE7 Inhibitors	183
11.7	Summary	184
	References	185
12	Inhibitors of Protozoan Phosphodiesterases as Potential Therapeutic Approaches for Tropical Diseases	191
	<i>Jennifer L. Woodring and Michael P. Pollastri</i>	
12.1	Introduction	191
12.2	Malaria	192
12.2.1	PfPDE Inhibition Studies	193
12.3	Chagas Disease	195
12.4	Leishmaniasis	197
12.5	Human African Trypanosomiasis	200
12.6	Conclusion	205
	References	206
	Index	211

